EUVIMED · CrossrefZeitschrift
Nucleic Acid Insights
ISSN 2977-4063 · BioInsights Publishing, Ltd.
Neueste Artikel
Fireside chat: AI’s emerging role in oligonucleotide development and manufacturing
AI across the RNA therapeutics lifecycle: discovery, development, and the road to personalized medicine
Polypeptide nanoparticles: a clinically validated, versatile delivery platform for RNA therapeutics
The chemistry and biology of oligonucleotide conjugation
Challenges and advances of the stability of mRNA delivery therapeutics
Production of mRNA by in vitro transcription utilizing a single-use system
Charting a course for the expanded application of mRNA vaccine technology
Pushing the boundaries of nucleic acid delivery
A brave new world of next-generation DNA applications in the biotherapeutics field
Harnessing the differentiated capabilities of mRNA for rare diseases
Wall Street analyst’s perspective: taking the pulse of the nucleic acid-based prophylactic & therapeutic vaccine sectors
Pioneering nucleic acid breakthroughs for the world
The evolving realm of nucleic acids: past, present, and future
Delivering on the promise of mRNA cancer vaccines in the immuno-oncology clinical setting
Comparative analysis of nucleic acid delivery systems for gene therapy: assessing viral and non-viral approaches with emphasis on extracellular vesicles
Glimpsing the future of siRNA delivery strategies and the broader therapeutic application of oligonucleotides
Corrigendum to: Scalable ultrafiltration/diafiltration process of clarified pDNA using T-series cassettes with Omega™ membrane
Pushing the boundaries of siRNA targeting and delivery
Key challenges and future opportunities for LNP-based delivery
Regulatory strategies for developing and manufacturing RNA-LNPs
MHRA regulatory considerations for the quality of mRNA products
Insights into manufacturing lab-scale in vitro transcribed RNA modalities
Moving mRNA–LNP therapeutics towards the clinic: overcoming myths and misconceptions to solve the specificity challenge
Exploring issues and opportunities in the development of platform technologies for oligonucleotide manufacturing
Taking a high-throughput approach to enhancing the target specificity and stability of nanoparticles
Self-amplifying RNA—opportunities and challenges
From bench to bedside: advancing mRNA therapies for cardiovascular diseases
Harnessing the potential of AI/ML to expand the horizons of the oligonucleotide therapeutics field
Delving into the unknowns of mRNA-LNP formulation and characterization
Downstream processing in the nucleic acids field: optimizing purification of mRNA and pDNA
EUVIMED